| 6.925 0.075 (1.09%) | 12-08 13:10 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.06  |
1-year : | 10.58 |
| Resists | First : | 7.76 |
Second : | 9.06 |
| Pivot price | 6.85  |
|||
| Supports | First : | 6.77 |
Second : | 6.16 |
| MAs | MA(5) : | 6.78 |
MA(20) : | 6.94 |
| MA(100) : | 7.08 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 48.1 |
D(3) : | 36.3 |
| RSI | RSI(14): 53.1 |
|||
| 52-week | High : | 17.12 | Low : | 5.71 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ EOLS ] has closed below upper band by 29.3%. Bollinger Bands are 60.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.91 - 6.94 | 6.94 - 6.97 |
| Low: | 6.68 - 6.71 | 6.71 - 6.74 |
| Close: | 6.8 - 6.85 | 6.85 - 6.9 |
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Fri, 05 Dec 2025
Stonepine Capital Management LLC Has $8.44 Million Holdings in Evolus, Inc. $EOLS - MarketBeat
Tue, 02 Dec 2025
Mizuho Maintains Evolus (EOLS) Outperform Recommendation - Nasdaq
Tue, 02 Dec 2025
Analyst Mizuho Lowers Price Target for Evolus (EOLS) to $19.00 | - GuruFocus
Thu, 27 Nov 2025
Evolus, Inc.'s (NASDAQ:EOLS) Path To Profitability - Yahoo Finance
Sun, 23 Nov 2025
Evolus, Inc. (NASDAQ:EOLS) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Fri, 14 Nov 2025
Evolus (NASDAQ: EOLS) grants 17,871 options at $6.56 under 2023 inducement plan - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 65 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 11.9 (%) |
| Held by Institutions | 84.4 (%) |
| Shares Short | 11,280 (K) |
| Shares Short P.Month | 13,250 (K) |
| EPS | -0.9 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.44 |
| Profit Margin | -20.5 % |
| Operating Margin | -14.8 % |
| Return on Assets (ttm) | -10.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 12.8 % |
| Gross Profit (p.s.) | 2.93 |
| Sales Per Share | 4.4 |
| EBITDA (p.s.) | -0.49 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -50 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -7.78 |
| PEG Ratio | 0 |
| Price to Book value | -15.9 |
| Price to Sales | 1.58 |
| Price to Cash Flow | -9.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|